$FOXA

Fox Corporation

  • NASDAQ
  • Consumer Services
  • Movies/Entertainment
  • Broadcasting
  • Information
  • Television Broadcasting

PRICE

$29.71 -

Extented Hours

VOLUME

2,867,378

DAY RANGE

29.345 - 29.88

52 WEEK

28.15 - 34.53

Join Discuss about FOXA with like-minded investors

profile
@cRUSTYTrades #ivtrades
recently

picked these up from uoa limit order i set earlier $FOXA 08/18 35 C

141 Replies 13 πŸ‘ 12 πŸ”₯

profile
@cRUSTYTrades #ivtrades
recently

$FOXA a possible pop coming soon,

141 Replies 15 πŸ‘ 11 πŸ”₯

profile
@thegiz18 #ivtrades
recently

$FOXA rocking on earnings

115 Replies 12 πŸ‘ 8 πŸ”₯

TR
@TraderJack #ivtrades
recently

haha, long $FOXA/short $NWS.....the tip for today.......byeeeeeeeeeeeeee........

91 Replies 6 πŸ‘ 10 πŸ”₯

profile
@dros #droscrew
recently

$FOXA Q3 Earnings Revenue: $3.05B vs. $2.91B Expected EPS: $1.11 vs. $1.00 Expected

138 Replies 15 πŸ‘ 8 πŸ”₯

profile
@dros #droscrew
recently

$FOXA Q3 Earnings Revenue: $3.05B vs. $2.91B Expected EPS: $1.11 vs. $1.00 Expected

140 Replies 9 πŸ‘ 9 πŸ”₯

profile
@dros #droscrew
recently

UNUSUALLY HEAVY OPTION VOLUME TODAY: ARISTA NETWORKS $ANET CLOROX $CLX ROCKWELL AUTOMATION $ROK FOX $FOXA SIMON PROPERTY GROUP $SPG

59 Replies 8 πŸ‘ 13 πŸ”₯

NI
@Nifty #LWT Trading
recently

BABA wise I hope I can get it to 5% allocation while in this area and then I'm looking at DISCA or FOXA dilema

104 Replies 8 πŸ‘ 8 πŸ”₯

profile
@DarkPoolAlgo #Dark Pool Charts
recently

Healthcare Moderna ($MRNA) Q2 EPS $6.46 vs. est. $6.04; Q2 revs $4.4B vs. est. $4.28B; expects dose capacity for its covid-19 vaccine in fy 2021 to be between 800 mln and 1 bln doses; advance purchase agreements signed for expected product sales of $20 bln in 2021, including sales already recorded in 6 months ended June 30; signed agreements for $12 bln worth of sales for covid-19 vaccine in 2022, option for about $8 bln more; continue to expect $450 mln -$550 mln of capital investments for 2021 Cigna ($CI) Q2 adj EPS $5.24 vs. est. $4.96; Q2 revs $43.13B vs. est. $41.31B; pharmacy customer base at Q2 grew to 101.9M, an organic increase of 3.1M year to date; total medical customer base at Q2 was 17M, an increase of 279,000 customers YTD; Q2 profit overall fell -16% hurt by higher medical costs; backs year EPS but ups its rev guidance to at least $170B from $166B Nevro ($NVRO) slides after withdrawing FY forecast on COVID-19 concerns and guided Q3 sales between $90M-$93M which is below analyst estimates of $114.7M Regeneron Pharma ($REGN) phase 3 Trial of Libtayo combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer Abiomed ($ABMD) Q1 adj EPS $1.10 vs. est. $1.05; Q1 revs $252.6M vs. est. $240.91M; raises FY22 revenue view to $1.03B-$1.05B from prior $990M-$1.03B (22%-24% growth); expects its fiscal year 2022 non-GAAP operating margin to be in the range of 24% to 26% Amedisys ($AMED) announces new $100M share repurchase program; Q2 adj EPS $1.69 vs. est. $1.67; Q2 revs $564.2M vs. est. $566.19M; guides 2021 adj EPS $6.37-$6.49 vs. est. $6.96; sees 2021 adj net service revenue $2.23B-$2.245B. Evolent Health ($EVH) 2Q EPS ($0.11) vs est. ($0.04) on revs $222.1Mm vs est. $216.9Mm; guides 3Q revs $215-230Mm vs est. $217.7Mm, sees FY revs $870-900Mm vs est. $870.8Mm; announces agreement to acquire Vital Decisions outstanding equity interests for aggregate price up to $130Mm, says transaction is accretive to EBITDA/share before synergies McKesson ($MCK) Q1 adj EPS $5.56 vs. est. $4.15; Q1 revs $62.7B vs. est. $59.99B; raises FY22 adj EPS view to $19.80-$20.40 from prior view $18.85-$19.45 (est. $19.23) 1life Healthcare, Inc. ($ONEM) Q2 EPS loss (-$0.30) vs. est. loss (-$0.20); Q2 revs $120.4M vs. est. $115.7M; sees Q3 revs $113M-$120M vs. est. $118M; sees year revs $475M-$485M vs. est. $482.3M; Membership count as of quarter-end was 621,000 compared to 475,000, a 31% increase; Adjusted EBITDA was positive $6.9 million, or 6% of net revenue Sarepta Therapeutics ($SRPT) Q2 non-GAAP EPS loss (-$1.52) vs. est. loss (-$1.26); net product sales for q2 reached $141.8 mln, a 27% increase over same quarter of prior year; raises full-year product revenue guidance by nearly $30 mln to between $565 mln to $575 mln Tandem Diabetes ($TNDM) 2Q revs $172.1Mm vs est. $143.4Mm; guides FY sales $670-685Mm vs est. $637Mm; guides FY adj EBITDA mgn about 15% vs est. 13.5% Industrials & Materials Albemarle ($ALB) Q2 adj EPS $0.89 vs. est. $0.83; Q2 revs $773.9M vs. est. $788.6M; qtrly lithium net sales of $320.3 mln increased $36.6 mln yoy primarily driven by higher volumes; full-year 2021 net sales guidance improved vs previous guidance primarily due to increased lithium sales, improving catalysts trends – sees year sales $3.3B-$3.4B vs. est. $3.24B Hillenbrand ($HI) 3Q adj EPS $0.85 vs est. $0.76 on revs $695Mm; guides 4Q adj EPS $0.82-0.92 vs est. $0.85, sees 4Q revs $713-738Mm vs est. $709.1Mm Maxar Technologies ($MAXR) 2Q EPS $0.60 vs est. $0.14 on revs $473Mm vs est. $441.5Mm Summit Materials ($SUM) 2Q EPS $0.48 vs est. $0.52 on revs $618.5Mm vs est. $647.1Mm; no change to FY guide Valvoline ($VVV) Q3 adj EPS $0.55 vs. est. $0.45; Q3 revs $792M vs. est. $745.32M; Q3 retail Services system-wide same-store sales grew 40.5%; Q3 same-store sales rose 27%; sees FY sales growth 25%-26% and FCF $250M-$270M Media & Telecom Fox Corp. ($FOXA) Q4 adj EPS $0.65 vs. est. $0.57; Q4 revs $2.89B vs. est. $2.75B; raises semi-annual dividend to 24c; cable network programming reported quarterly segment revenues of $1.40B, an increase of $128M; affiliate revenues increased 10% with 16% growth at the television segment and 6% growth at the cable network programming segment in q4 Roku Inc. ($ROKU) Q2 EPS 52c vs est. 13c on revs $645M vs est. $618.4M, average rev per user $36.46 (+46% YoY), active accounts 55.1M vs est. 55.8M; at midpoint of Q3 guidance, sees revs $675M-$685M vs est. $645M, gross profit $315M-$325M, adj EBITDA $60M-$70M, net income (-$3M)-$7M, anticipates sequential increases in operating expenses in 2H from investments in headcount, product development, and sales & marketing Technology Amdocs Ltd. ($DOX) 3Q adj EPS $1.35 vs est. $1.18 on revs $1.066B vs est. $1.06B; guides 4Q adj EPS $1.13-1.19 vs est. $1.28, sees 4Q revs $1.065-1.105B vs est. $1.087B Booking Holdings ($BKNG) 2Q adj EPS ($2.55) vs est. ($2.04) on revs $2.2B vs est. $1.9B, encouraged by sequential improvement in booking trends with 2Q room nights +59% vs 1Q; said in in q2, we saw the first sequential increase in the number of properties on booking.com and lowest number of properties coming off of our platform since the onset of the covid-19 pandemic DXC Technology ($DXC) Q1 adj EPS $0.84 vs. est. $0.74; Q1 revs $4.14B vs. est. $4.11B; Q2 guidance falls short of views but backs year EPS view $3.45-$3.65 vs. est. $3.56 and backs FY22 revenue view $16.6B-$16.8B (est. $16.74B); Bookings of $4.6 billion and book-to-bill ratio of 1.12x in Q1 FY22 Electronic Arts ($EA) Q1 EPS $0.71 vs. est. $0.62; Q1 net bookings $1.336B vs. est. $1.28B; sees Q2 EPS roughly $0.36 vs. est. $1.07; sees Q2 net bookings $1.725B vs. est. $1.62B; raises FY22 EPS view to $1.58 from $1.34 and ups FY21 bookings view to $7.4B from $7.3B Fastly Inc. ($FSLY) shares fall -18%; Q2 adj EPS ($$0.15) vs est. ($0.17) on revs $85.03M vs est. $85.7M, sees Q3 EPS loss (21c)-(18c) vs est. (18c) on revs $82M-$85M vs est. $97.9M, and forecasts FY EPS (65c)-(57c) vs est. (43c) on revs $340M-$350M vs est. $382.5M GoDaddy ($GDDY) Q2 EPS $0.27 vs. est. $0.32; Q2 revs $931.3M vs. est. $919.7M; total bookings of $1.055B, up 12.7% year over year, or 10.6% on a constant currency basis; Domains revenue of $436.7 million, up 18.2% yoy; Hosting and presence revenue of $318.5 million, up 9.0% yoy; Business applications revenue of $176.1 million, up 21.8% yoy; sees year revs $3.75B, in-line HubSpot ($HUBS) 2Q adj EPS $0.43 vs est. $0.32 on revs $310.8Mm vs est. $296Mm; guides 3Q adj EPS $0.42-0.44 vs est. $0.39, sees 3Q revs $325-327Mm vs est. $318.7Mm; guides FY revs $1.268-1.272B vs est. $1.244B MercadoLibre ($MELI) Q2 EPS $1.37 vs est. $0.19 on revs $1.7B vs est. $1.48B with commerce revs +96.4% YoY and fintech revs +88.9%; unique active users 75.9M in quarter (+47.4% YoY), total payment volume through Mercado Pago topped $17.5B (+56.3% in USD), gross merchandise volume $7B (+39.2% in USD) Ping Identity ($PING) 2Q adj EPS $0.11 vs est. $0.04 on revs $78.9Mm vs est. $66.1Mm; guides 3Q revs $65-70Mm vs est. $65.1Mm, sees 3Q total ARR $286-288Mm; guides FY revs $278-285Mm vs est. $269.3Mm, sees FY total ARR $304-306Mm Qorvo ($QRVO) Q1 EPS $2.83 vs. est. $2.45; Q1 revs $1.11B vs. est. $1.08B; sees Q2 EPS $3.24 at midpoint vs. est. $3.02; sees Q2 revenue $1.24B-$1.26B vs. est. $1.21B Trimble Inc. ($TRMB) Q2 adj EPS $0.72 vs. est. $0.59; Q2 revs $945.3M vs. est. $867.8M; sees FY21 adj EPS $2.45-$2.65 vs. est. $2.45; sees FY21 adjusted revenue $3.55B-$3.65B vs. est. $3.48B; Q2 annualized recurring revenue (ARR) was $1.35 billion, up 11% yoy Western Digital ($WDC) 4Q adj EPS $2.16 vs est. $1.51 on revs $4.9B vs est. $4.55B; guides 1Q revs $4.9-5.1B vs est. $4.9B, sees 1Q adj EPS $2.25-2.55 vs est. $2.05

52 Replies 9 πŸ‘ 15 πŸ”₯

profile
@DarkPoolAlgo #Dark Pool Charts
recently

Wednesday, August 4, 2021 Futures Up/Down % Last Dow -25.00 0.07% 34,973 S&P 500 -1.25 0.04% 4,413 Nasdaq 11.50 0.08% 15,058 U.S. S&P futures are flat heading into the trading day, looking to build on record highs from Tuesday as positive earnings boost U.S and European stocks while worries over China’s gaming and technology crackdown ease, helping lift those markets. Risk sentiment improves across Asia as Chinese and Hong Kong stocks push higher on tech recovery and solid Caixin PMI data. In Asian markets, The Nikkei Index fell -57 points to 27,854, the Shanghai Index rose 29 points to 3,477 and the Hang Seng Index jumped 231 points to settle at 26,426. In Europe, the German DAX is climbing around 125 points to 15,680, while the FTSE 100 is up 0.4% to 7,135. Chinese Jul Caixin Services PMI beat: 54.9 vs 50.6 consensus. Some also see the spread of the Covid-19 delta variant as delaying rather than stopping the economic recovery. The New York Times reported overnight that the FDA plans to give full approval to Pfizer (PFE) and BioNTech (BNTX) coronavirus vaccine by the start of the next month. Earnings season has been strong with about 87% of S&P 500 companies reporting earnings and revenue beats, according to FactSet. Just under 70% of the S&P 500 now has reported earnings. The S&P 500 closed at record highs with gains in Apple and healthcare stocks, as concerns over a surge in the Delta variant of the coronavirus was put to the back-burner, overshadowed by continued upbeat corporate earnings. Ten of the 11 S&P indexes traded higher, with energy stocks rebounding after getting hit by a dip in oil prices. Market Closing Prices Yesterday The S&P 500 Index gained 35.99 points, or 0.82%, to 4,423.15 The Dow Jones Industrial Average rose 278.24 points, or 0.80%, to 35,116.40 The Nasdaq Composite climbed 80.23 points, or 0.55%, to 14,761.29 The Russell 2000 Index advanced 8.09 points, or 0.36% to 2,223.58 Events Calendar for Today 7:00 AM ET MBA Mortgage Applications Data 8:15 AM ET ADP Employment Change for July…est. 695K 9:45 AM ET Markit Composite PMI, July-F 9:45 AM ET Markit Services PMI, July-F 10:00 AM ET ISM Non-Manufacturing Services PMI for July…est. 60.5 10:30 AM ET Weekly DOE Inventory Data Earnings Calendar: Earnings Before the Open: ABC, AEIS, ALE, APO, ASTE, BCOR, BDC, BGCP, BWA, CDW, CLVS, CLH, CLW, CMLS, CRL, CSII, DNOW, DOC, EDIT, EMR, ETR, EXC, FLOW, FUN, GEL, GM, HDSN, HFC, HZNP, IONS, JLL, KHC, LL, MAC, MKL, MPC, MPLX, MTOR, NI, NYT, ODP, RCL, SBGI, SGRY, SITE, SMG, SPR, SUP, TGI, TUP, TXMD, UTHR, VCEL, VMC, WLL Earnings After the Close: ACAD, ACLS, ADPT, ADTN, AGL, ALB, ALL, AMED, ANGI, ANSS, APA, ATO, AXGN, BBSI, BE, BFAM, BKNG, BOOT, CCMP, CDAY, CENX, CHNG, CMP, CPS, DGII, DOX, DVAX, DXC, EA, EGHT, ELF, EMKR, EOG, ETSY, EVH, FLT, FOXA, FSLY, FTDR, GDDY, GNK, HI, HUBS, IAC, INGN, IVR, JACK, LESL, LNC, LPI, LUMN, MAXR, MBI, MCK, MED, MET, MGM, MOD, MRO, MTG, NUS,NVRO, ONEM, PARR, PDCE, $PING, PLYA, QRVO, QTWO, RCII, REGI, RGR, RMAX, RNWK, EOKU, RPD, $RVLV, RYN, SBRA, SMSI, SUM, T$NDM, TPC, TTGT, TVTY, TWNK, TWO, TXG, $UBER, UHAL, VVV, VZIO, WDC, WU, YELL Other Key Events: Jefferies Industrials Conference (virtual), 8/3-8/4 Piper Wealth Management Forum (virtual), 8/3-8/6 Macro Up/Down Last Nymex -0.34 70.22 Brent -0.18 72.23 Gold 3.30 1,813.75 EUR/USD -0.0008 1.1856 JPY/USD 0.13 109.17 10-Year Note +0.008 1.182% Sector News Breakdown Consumer Caesar’s Entertainment ($CZR) Q2 EPS $0.34 vs. est. loss (-$0.26); Q2 revs $2.5B vs. est. $2.27B; Q2 same-store Adjusted EBITDA was $1B versus (-$131M) for the comparable prior-year period; Company posted all-time records in quarterly Adjusted EBITDA and Adjusted EBITDA margin. Denny’s ($DENN) Q2 adj EPS $0.18 vs. est. $0.11; Q2 revs $106.2M vs. est. $98.1M; Q2 domestic system-wide same-store sales decreased 1.2% compared to the equivalent fiscal period in 2019, including a 1.5% decrease at domestic franchised restaurants and a 1.9% increase at company restaurants. Herbalife ($HLF) Q2 adj EPS $1.52 vs. est. $1.29; Q2 revs $1.55B vs. est. $1.57B; Q2 adjusted EBITDA of $262.1M; raises FY21 EPS view to $4.70-$5.10 from $4.65-$5.05 (est. $4.93); sees FY net sales growth to be in a range of 8.5% to 12.5%, lowering the midpoint by 150 basis points compared to prior full year 2021 guidance. Host Hotels ($HST) Q2 adj FFO $0.12 vs. est. $0.04; Q2 revs $649M vs. est. $606.58M; said RevPAR reached nearly $100 for the quarter, which dramatically outperformed consensus RevPAR, with average room rates only 8.4% below our 2019 second quarter rates; not providing year guidance Hyatt ($H) 2Q adj EPS ($1.15) vs est. ($0.85) on comparable system-wide REVPAR $72.47, qtrly total revs $663Mm vs est. $686.9Mm; guides FY net rooms growth more than +6%, sees FY adj SG&A about $240Mm, sees FY CAPEX about $110Mm Energy Devon Energy ($DVN) Q2 adj EPS $0.60 vs est. $0.52 on revs $2.42B vs est. $2.35B, operating cash flow $1.1B, production for the quarter averaged 291k barrels/day; will pay total dividend of 49c/shr (11c fixed + 38c variable), a 44% increase from Q1; sees 3q production 566-594 mboe/d vs est. 564.80 mboe/d Occidental Petroleum ($OXY) Q2 adj EPS 32c vs est. 1c on revs $5.96B vs est. $5.92B, FCF $2B, cash flow from continuing operations $3.3B; said oil and gas results improved from Q1 due to higher commodity prices and sales volumes; executed debt tender offer and repaid over $3B of long-term debt in July ONEOK ($OKE) Q2 EPS $0.77 vs. est. $0.75; Q2 revs $3.39B vs. est. $3.03B; sees 2021 net income, adj earnings before interest, taxes, depreciation, amortization to be above midpoints of ranges provided on April 27, 2021 SunPower ($SPWR) Q2 adj EPS $0.06 vs. est. $0.04; Q2 revs $308.9M vs. est. $327.31M; guides Q3 revs $325M-$375M vs. est. $400.83M; sees Q3 GAAP net loss of $10 to $0 million and MW recognized of 125 MW to 150 MW; Q2 added 13,000 residential customers – residential bookings up 16 percent sequentially, 67 percent year-over-year (YoY) The American Petroleum Institute ($API) showed a draw of 879K barrels of oil for the latest week; gasoline inventories show a draw of 5.75M barrels, distillate inventories show a draw of 717K barrels and Cushing inventories show a build of 659K barrels W&T Offshore ($WTI) Q2 EPS $0.02 vs. est. $0.07; Q2 revs $132.8M vs. est. $122.38M; Q2 Production was 40,888 Boe/d or 3.7 MMBoe, an increase of 3% compared to 39,657 Boe/d in Q1 and down 3% versus 42,037 Boe/d in Q2 of 2020 Financials Assurant Inc. ($AIZ) Q2 operating EPS $2.99 vs. est. $2.45; Q2 revs $2.54B vs. est. $2.39B; continue to expect to grow eps, ex. catastrophes, by 10 to 14 percent for 2021 Fair Isaac ($FICO) Q3 non-GAAP EPS $3.38 vs. est. $2.76; Q3 revs $338M vs. est. $328.3M; Applications revenues, which include the company’s decision management applications and associated professional services, were $133.2 million in the third quarter, compared to $141.5 million in the prior year period, a decrease of 6% Genworth Financial ($GNW) Q2 adj EPS $0.38 vs. est. $0.22; Q2 revs $2.04B vs. est. $1.9B; planned IPO of Enact remains a key strategic objective for Genworth and is subject to market and other conditions, however because the company is in registration and subject to applicable publicity restrictions, is unable to comment further or provide any additional detail at this time. Green Dot ($GDOT) Q2 adj EPS $0.68 vs est. $0.43 on revs $369.4M vs est. $313.2M; sees FY21 adj EPS $2.13-$2.27 vs prev. $2.06-$2.15, revs $1.33B-$1.35B vs est. $1.28B Prudential ($PRU) Q2 adj EPS $3.79 vs. est. $3.02; qtrly book value per common share of $160.31 versus $165.53 per share for year-ago; qtrly adjusted book value per common share of $104.39 versus $92.07 per share for year-ago; qtr end assets under management of $1.730 trillion versus $1.605 trillion for year-ago; now expect to return a total of $11.0B to holders from $10.5B prior Tanger Outlets ($SKT) 2Q core FFO/shr $0.43 vs est. $0.28, portfolio occupancy was 93% on June 30 vs 91.7% on March 31, avg tenant sales productivity was $424/sq ft for 12 months ended June 30 +7.3% yr/yr; guides FY FFO/shr $1.52-1.59 vs est. $1.46 Unum Group (UNM) Q2 adj EPS $1.39 vs. est. $1.11; Q2 revs $2.99B vs. est. $2.96B; Full-year 2021 outlook increased; after-tax adjusted operating income per share now expected to decline 1%-3% relative to full-year 2020, compared to an expected decline of 5%-6% prior Verisk Analytics ($VRSK) Q2 adj EPS $1.17 vs. est. $1.33; Q2 revs $747.5M vs. est. $737.3M; Net cash provided by operating activities was $233.2 million, down 6.5% for the second quarter of 2021. Free cash flow, a non-GAAP measure, was $170.7 million, down 11.5% Healthcare Change Healthcare ($CHNG) shares fell over 7% on a report that the U.S. Dept. of Justice is considering a lawsuit to block the company’s $8B sale to UnitedHealth ($UNH) https://bit.ly/3yA4Etu Option Care Health ($OPCH) 18M share Spot Secondary priced at $20.25 Amgen Inc. ($AMGN) Q2 adj EPS $4.38 vs. est. $4.06; Q2 revs $6.5B vs. est. $6.43B; backs FY21 adj EPS view $16.00-$17.00 vs. est. $16.34; backs FY21 revenue view $25.8B-$26.6B vs. est. $26.04B Amid surge in new COVID-19 infections across U.S., the FDA plans to give full approval to Pfizer (PFE) – BioNTech (BNTX) coronavirus vaccine by the start of the next month, The New York Times reports The FDA classified the recent recall of some of Philips’ (PHG) ventilators as Class 1, or the most serious type of recall, saying the use of these devices may cause serious injuries or death – Reuters CVS Health ($CVS) Q2 adj EPS $2.42 vs. est. $2.06; Q2 revs $72.62B vs. est. $70.11B; raises FY21 adjusted EPS view to $7.70-$7.80 from $7.56-$7.68 (est. $7.66); sees FY21 cash flow from operations $12.5B-$13B DaVita Inc. (DVA) 2Q EPS $2.64 vs est. $2.17; says total US dialysis treatments for 2Q were 7,413497 (avg 95,045/day); guides FY adj EPS $8.80-9.40 vs est. $8.63, sees FY adj op income $1.8-1.875B vs est. $1.816B Inspire Medical ($INSP) 2Q EPS ($0.48) vs est. ($0.64) on revs $53Mm vs est. $43.9Mm; guides FY revs $210-213Mm vs est. $195.9Mm, sees FY gr mgn 85-86%, sees opening 48-52 new US medical centers per qtr for 2H Jazz Pharma ($JAZZ) Q2 adj EPS $3.90 vs. est. $3.42; Q2 revs $751.8M vs. est. $735.62M; reaffirms FY21 non-GAAP EPS view $13.40-$14.70 (est. $14.45) and also back FY21 revenue view $3.020B-$3.180B vs. est. $3.11B; as of June 30, cash, cash equivalents were $891.4 mln, and outstanding principal balance of co’s long-term debt was $7.1 bln

147 Replies 10 πŸ‘ 11 πŸ”₯

profile
@DarkPoolAlgo #Dark Pool Charts
recently

/*============================================= = Friday, June 18, 2021 = =============================================*/ Futures Up/Down % Last Dow -39.00 0.12% 33,654 S&P 500 -2.25 0.08% 4,209 Nasdaq 26.50 0.18% 14,182 U.S. futures are looking mixed again, looking much like yesterday’s closing levels when the Nasdaq Composite closed at a new all-time high as Treasury yields dropped across the board (10-yr yield fell back around the 1.5% level), boosting growth stocks, while a steep drop in shares of energy, banks, materials and industrials weighed on the S&P 500 and SmallCap Russell 2000. The S&P 500 Banks index plunged more than 4% for its worst day since June 2020, led by Dow components JPM and Goldman, while Citigroup shares dropped an 11th straight day. In Asian markets, The Nikkei Index fell -54 points to 28,964, the Shanghai Index was little changed at 3,525, and the Hang Seng Index rose 242 points to 28,801. In Europe, the German DAX is lower by about 70 points to 15,650, while the FTSE 100 is down around 55 points to dip below 7,100. On Wednesday, the Fed forecast that it likely will raise rates two times by the end of 2023 and Chairman Jerome Powell said the central bank has begun discussing when to begin pulling back on bond purchases of $120 billion a month. Stocks fell initially on those headlines but have since found solid footing with a rotation back into high growth names and out of the relation names with commodities, energy and financials in free fall the last two-days. Market Closing Prices Yesterday The S&P 500 Index slipped -1.84 points, or 0.04%, to 4,221.86 The Dow Jones Industrial Average fell -210.22 points, or 0.62%, to 33,823.45 The Nasdaq Composite jumped 121.67 points, or 0.87%, to 14,161.35 The Russell 2000 Index declined -27.23 points, or 1.18% to 2,287.46 Events Calendar for Today 1:00 PM EST Baker Hughes Weekly rig count data Macro Up/Down Last Nymex -0.23 70.81 Brent -0.35 72.73 Gold 18.30 1,791.80 EUR/USD 0.0013 1.1920 JPY/USD -0.09 110.12 10-Year Note -0.022 1.489% Sector News Breakdown Consumer Smith & Wesson Brands ($SWBI) Q4 GAAP EPS $1.71 vs. est. $1.02; Q4 revs $322.9M vs. est. $259.8M; raises dividend 60% to $0.08 and announces new $50M share buyback plan; Q4 gross margin 45.1% vs. 32.2% last year Energy, Industrials and Materials S. Steel ($X) guides Q3 adj EPS approx $3.08 vs. est. $2.67; Q2 adjusted Ebitda is expected to be approximately $1.2B; and Q2 adj net income is expected to be about $880M and excludes impacts primarily related to certain restructuring and asset impairment charges; to fully redeem senior notes due 2025 CAI International ($CAI) to be acquired by Mitsubishi HC Capital Inc. in an all-cash transaction for $56.00 per share, which represents a total equity value of approximately $1.1B Mammoth Energy ($TUSK) files to sell 24.1M shares of common stock for holders Alaska Air ($ALK) and Delta Air ($DAL) upgraded to Outperform from Peer Perform at Wolfe Research and United Airlines ($UAL) upgraded to Peer Perform from Underperform Occidental ($OXY) upgraded to Overweight from Equal Weight, Marathon Oil ($MRO) upgraded to Equal-weigh at Morgan Stanley, while the firm downgraded Devon Energy ($DVN), EQT Corp. ($EQT) and Cimarex Energy ($XEC) to Equal-weight ArcelorMittal North America Holding, a wholly-owned subsidiary of ArcelorMittal SA ($MT) to sell its remaining 38.2M common shares in Cleveland-Cliffs ($CLF) and to use proceeds for new $750M share buyback program. Financials LPL Financial ($LPLA) reported total brokerage and advisory assets for May of +44% vs. +3.90% YoY; May brokerage, advisory assets $1.07 trillion Ares Commercial ($ACRE)5M share Spot Secondary priced at $15.82 Healthcare Athira Pharma Inc.’s ($ATHA) CEO Leen Kawas has been put on temporary leave as the board reviews actions stemming from doctoral research while at Washington State University, the company said Thursday. Geron Corp ($GERN) rises after reporting positive data from a mid-stage study of blood cancer treatment imetelstat, which showed benefits including symptom response and overall survival in patients with myelofibrosis, a chronic blood cancer Ambrx Biopharma ($AMAM) 7M share IPO priced at $18.00 Codex DNA ($DNAY)67M share IPO priced at $16.00 Codexis ($CDXS) raises 2021 revenue view to $89M-$93M from $82M-$85M (est. $83.74M) following the receipt of a binding purchase order for up to $13.9M of a proprietary high performance enzyme product from an undisclosed global pharmaceutical company Century Therapeutics ($IPSC)6M share IPO priced at $20.00 Cyteir Therapeutics ($CYT)4M share IPO priced at $18.00 Technology, Media & Telecom Adobe Systems ($ADBE) Q2 adj EPS $3.03 vs. est. $2.82: Q2 revs $3.84B vs. est. $3.73B; Q2 Digital Media segment revenue was $2.79 billion, which represents 25% YoY; creative revenue grew to $2.32 billion, representing 24% YoY; Document Cloud revenue was $469 million, representing 30% YoY growth; sees Q3 total revenue about $3.88B (vs. est. $3.83B) Fox Corporation ($FOXA) announces $2 billion incremental stock repurchase authorization Spotify ($SPOT) is announced its acquired Podz, a small team working to improve podcast discovery Tremor International ($TRMR)76M share ADS priced at $19.00

98 Replies 9 πŸ‘ 10 πŸ”₯

profile
@dros #droscrew
recently

2782 $FOXA MAY2021 $40 Cs bought 0.998

114 Replies 6 πŸ‘ 8 πŸ”₯

profile
@dros #droscrew
recently

2782 $FOXA MAY2021 $40 Cs bought 0.998

117 Replies 15 πŸ‘ 14 πŸ”₯

profile
@ivtrades-Chris #ivtrades
recently

SWEEP DETECTED: >>1500 $FOXA Oct21 39.0 Calls trade $3.30 (FT Theo=3.16) ASKSIDE [MULTI] IV=37.9% -0.8 ISO - OPENING Vol=1500, OI=423

59 Replies 10 πŸ‘ 13 πŸ”₯

profile
@CarlosH-carvan #ivtrades
recently

$FOXA Apr 48C volume 3,056 vs OI 211

53 Replies 10 πŸ‘ 7 πŸ”₯

profile
@ivtrades-Chris #ivtrades
recently

SWEEP DETECTED: >>1811 $FOXA Apr21 36.0 Calls trade $4.50 ASKSIDE [MULTI] 10:57:51 IV=46.1% +1.3 ISO - OPENING Vol=1852, OI=941

115 Replies 10 πŸ‘ 11 πŸ”₯

profile
@dros #droscrew
recently

5000 $FOXA MAR2021 $33 Cs bought 1.29, rolled from 12FEB2021 $31 Cs

108 Replies 9 πŸ‘ 7 πŸ”₯

profile
@dros #droscrew
recently

7500 $FOXA 12FEB2021 $33 Cs bought 0.48

94 Replies 7 πŸ‘ 15 πŸ”₯

profile
@dros #droscrew
recently

7500 $FOXA 12FEB2021 $33 Cs bought 0.48

46 Replies 9 πŸ‘ 12 πŸ”₯

profile
@CarlosH-carvan #ivtrades
recently

4Th day $FOXA scan PUT

129 Replies 8 πŸ‘ 10 πŸ”₯

profile
@CarlosH-carvan #ivtrades
recently

6750 FOXA Jul20 24th 29.0 Calls $0.35

52 Replies 12 πŸ‘ 13 πŸ”₯

Key Metrics

Market Cap

13.41 B

Beta

0.67

Avg. Volume

3.58 M

Shares Outstanding

239.30 M

Yield

1.75%

Public Float

0

Next Earnings Date

2024-05-07

Next Dividend Date

Company Information

fox corporation produces and distributes compelling news, sports and entertainment content through its iconic domestic brands including: fox news, fox sports, the fox network, and the fox television stations. these brands hold cultural significance with consumers and commercial importance for distributors and advertisers. the breadth and depth of our footprint allows us to deliver content that engages and informs audiences, develops deeper consumer relationships and creates more compelling product offerings. fox maintains an impressive track record of news, sports, and entertainment industry success that will shape our strategy to capitalize on current strengths and invest in new initiatives. for more information about fox corporation, please visit www.foxcorporation.com.

CEO: Lachlan Murdoch

Website:

HQ: 1211 Avenue of the Americas New York, 10036-8701 New York

Related News